Suchergebnisse - "71050168A2"

PubPharm (298)

1

A phase 1-2 trial of DA-EPOCH-R plus ixazomib for MYC-aberrant lymphoid malignancies : the DACIPHOR regimen

enthalten in: Blood advances | 2024

von Karmali, R. | Galvez, C. | Hamadani, M. | +14

2

INSURE : a pooled analysis of ixazomib-lenalidomide-dexamethasone for relapsed/refractory myeloma in routine practice

enthalten in: Future oncology (London, England) | 2024

von Leleu, X. | Lee, H. | Zonder, J. | +10

3

In vivo activity of the second-generation proteasome inhibitor ixazomib against pediatric T-cell acute lymphoblastic leukemia xenografts

enthalten in: Experimental hematology | 2024

von Randall, J. | Evans, K. | Watts, B. | +10

4

A real-world retrospective-prospective analysis of efficacy and safety of combined ixazomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma : The northern Italy experience

enthalten in: Cancer medicine | 2024

von Furlan, A. | Cea, M. | Pavan, L. | +25

5

Use Via Early Access to Ixazomib (UVEA-IXA) Study : Effectiveness and Safety of Ixazomib-based Therapy in Relapsed/Refractory Multiple Myeloma Outside of the Clinical Trial Setting

enthalten in: Clinical lymphoma, myeloma & leukemia | 2024

von Ludwig, H. | Ramasamy, K. | Mateos, M. | +10

6

Effect of proteasome inhibitors on canine lymphoma cell response to CHOP chemotherapy in vitro

enthalten in: Veterinary and comparative oncology | 2024

von Prevedel, N. | Mee, M. | Wood, G. | +1

7

Efficacy and safety of daratumumab with ixazomib and dexamethasone in lenalidomide-exposed patients after one prior line of therapy : Final results of the phase 2 study DARIA

enthalten in: American journal of hematology | 2024

von Terpos, E. | Ntanasis-Stathopoulos, I. | Gavriatopoulou, M. | +11

8

Molecular insights into the dynamic modulation of bacterial ClpP function and oligomerization by peptidomimetic boronate compounds

enthalten in: Scientific reports | 2024

von Alves França, B. | Falke, S. | Rohde, H. | +1

9

A prospective, multicenter, observational study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in Japan

enthalten in: Annals of hematology | 2024

von Horigome, Y. | Iino, M. | Harazaki, Y. | +22

10

Complete pathological response of hormone receptor positive invasive breast cancer in a patient with multiple myeloma treated with ixazomib

enthalten in: Tumori | 2023

von Dameri, M. | Garlaschi, A. | Cuccarolo, P. | +8

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[30]